Adverse cardiovascular outcomes of corticosteroid excess

Endocrinology

Volumn 153, Issue 11, 2012, Pages 5137-5142

  Pimenta, Eduardo ^a   Wolley, Martin ^a   Stowasser, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOCORTICOID; LOOP DIURETIC AGENT; MINERALOCORTICOID RECEPTOR; PREDNISONE; SPIRONOLACTONE;

ADD ON THERAPY; ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CUSHING SYNDROME; HEART OUTPUT; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY INJURY; METABOLIC SYNDROME X; OBESITY; PLASMA VOLUME; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SALT INTAKE; SHORT SURVEY; VASCULAR RESISTANCE;

ADRENAL CORTEX HORMONES; ANIMALS; CARDIOVASCULAR SYSTEM; CUSHING SYNDROME; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RISK FACTORS;

EID: 84867783052     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1573     Document Type: Short Survey

References (52)

1. Plotz CM, Knowlton AI, Ragan C 1952 The natural history of Cushing's syndrome. Am J Med 13:597-614
2. Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler Jr GB, Nieman LK, Chrousos GP 1994 Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 331:629-636
3. Williamson PM, Kelly JJ, Whitworth JA 1996 Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 14:S37-S41 (Pubitemid 27051076)
4. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R 1987 Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 5:425-433 (Pubitemid 17126233)
5. Whitworth JA, Saines D, Scoggins BA 1984 Blood pressure and metabolic effects of cortisol and deoxycorticosterone in man. Clin Exp Hypertens A 6:795-809 (Pubitemid 14134546)
6. Connell JM, Whitworth JA, Davies DL, Richards AM, Fraser R 1988 Haemodynamic, hormonal and renal effects of adrenocorticotrophic hormone in sodium-restricted man. J Hypertens 6:17-23 (Pubitemid 18063296)
7. Saruta T 1996 Mechanism of glucocorticoid-induced hypertension. Hypertens Res 19:1-8
8. Whitworth JA, Gordon D, Andrews J, Scoggins BA 1989 The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 7:537-549 (Pubitemid 19189576)
9. Thunhorst RL, Beltz TG, Johnson AK 2007 Glucocorticoids increase salt appetite by promoting water and sodium excretion. Am J Physiol Regul Integr Comp Physiol 293:R1444-R1451 (Pubitemid 47358971)
10. Whitworth JA, Williamson PM, Mangos G, Kelly JJ 2005 Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 1:291-299
11. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T 1994 Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 23:25-30 (Pubitemid 24022040)
12. Gordon RD, Klemm SA, Tunny TJ, Stowasser M 1992 Primary aldosteronism: hypertension with a genetic basis. Lancet 340:159-161
13. Stowasser M 2009 Update in primary aldosteronism. J Clin Endocrinol Metab 94:3623-3630
14. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE 2003 Primary aldosteronism and hypertensive disease. Hypertension 42:161-165 (Pubitemid 36944590)
15. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM 2008 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51:1403-1419
16. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA 2008 Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168:1159-1164 (Pubitemid 351831398)
17. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, Walker BR 2004 Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 90:859-865 (Pubitemid 39005927)
18. Wei L, MacDonald TM, Walker BR 2004 Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764-770
19. Davis 3rd JM, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE 2007 Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56:820-830 (Pubitemid 46399429)
20. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T 2011 Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 78:23-30
21. Clayton RN, Raskauskiene D, Reulen RC, Jones PW 2011 Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632-642
22. Swearingen B, Biller BM, Barker 2nd FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT 1999 Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130:821-824 (Pubitemid 29231150)
23. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB 2004 Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:6348-6357 (Pubitemid 39628458)
24. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA 2007 Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976-981 (Pubitemid 46465672)
25. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM 2007 Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403-414 (Pubitemid 46135879)
26. Galassi A, Reynolds K, He J 2006 Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119:812-819 (Pubitemid 44415613)
27. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ 2010 The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113-1132
28. Walker BR 2007 Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545-559 (Pubitemid 350187371)
29. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248 (Pubitemid 40523144)
30. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA 2008 Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168:80-85
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717 (Pubitemid 29407370)
32. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321 (Pubitemid 36384098)
33. Funder JW 2010 Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 151:5098-5102
34. Young MJ 2008 Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 17:174-180 (Pubitemid 351253043)
35. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA 2007 Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50:911-918 (Pubitemid 350287534)
36. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC 1997 Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95:1471-1478 (Pubitemid 27142805)
37. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH 2005 Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90:5070-5076 (Pubitemid 41262256)
38. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A 2003 Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527-2533 (Pubitemid 36724418)
39. Després JP, Lemieux I 2006 Abdominal obesity and metabolic syndrome. Nature 444:881-887 (Pubitemid 46024995)
40. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G 1999 Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84:2664-2672 (Pubitemid 30641990)
41. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU 2012 Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 97:1702-1711
42. Schäcke H, Döcke WD, Asadullah K 2002 Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43 (Pubitemid 35346616)
43. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J 1994 Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154:97-101 (Pubitemid 24018107)
44. Pimenta E, Calhoun DA 2009 Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension 53:585-586
45. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF 2009 Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 53:605-610
46. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA 2007 Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30:2349-2354 (Pubitemid 47359046)
47. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE 2007 A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 25:2125-2130 (Pubitemid 47476311)
48. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901 (Pubitemid 23002899)
49. Young MJ, Rickard AJ 2012 Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 350:248-255
50. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, Stowasser M 2011 Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab 96:2813-2820
51. du Cailar G, Fesler P, Ribstein J, Mimran A 2010 Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 56:865-870
52. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA 2008 Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 51:339-344 (Pubitemid 351159948)